The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PetMed Express' revenues will expand 4.4% and EPS will increase 4.5%.
The average estimate for revenue is $76.8 million. On the bottom line, the average EPS estimate is $0.23.
Last quarter, PetMed Express logged revenue of $55.9 million. GAAP reported sales were 9.8% higher than the prior-year quarter's $50.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.20. GAAP EPS of $0.19 for Q4 were 5.6% higher than the prior-year quarter's $0.18 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 33.9%, 40 basis points worse than the prior-year quarter. Operating margin was 11.2%, 150 basis points worse than the prior-year quarter. Net margin was 7.1%, 100 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $245.9 million. The average EPS estimate is $0.78.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 866 members out of 895 rating the stock outperform, and 29 members rating it underperform. Among 222 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 212 give PetMed Express a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PetMed Express is underperform, with an average price target of $11.00.
While many retailers continue to struggle in these tough economic times, a select few are changing the face of the business and reaping outsized rewards. Is PetMed Express the right stock for you? Read "The Death of Wal-Mart: The Real Cash Kings Changing the Face of Retail" and decide. Click here for instant access to this free report.
- Add PetMed Express to My Watchlist.